Drug Profile
Follitropin alfa biosimilar - Alphamab
Alternative Names: LM-001; Recombinant human Follicle Stimulating Hormone - Alphamab; rhFSH - AlphamabLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
- Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Female infertility
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Female-infertility in China (SC, Injection)
- 12 Jul 2019 LM 001 is still in preclinical trials for Female infertility in China (Alphamab pipeline, July 2019)
- 24 May 2018 Alphamab plans a phase I trial in healthy volunteers (In women) in June 2018 (NCT03535103)